Equities

Episurf Medical AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Episurf Medical AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.0419
  • Today's Change0.003 / 6.35%
  • Shares traded32.26m
  • 1 Year change-48.75%
  • Beta0.7357
Data delayed at least 15 minutes, as of Feb 10 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Episurf Medical AB is a Sweden-based company primarily engaged in the medical device industry. The Company scope of activity includes developing and commercializing patient-specific implants and surgical instruments for the treatment of joint injuries, particularly in the knee and ankle. Their key product is Episealer, which is a customized implant system. It is designed to treat localized cartilage damage and early-stage osteoarthritis by adapting the implant and associated surgical tools to the individual anatomy and injury of each patient.

  • Revenue in SEK (TTM)15.60m
  • Net income in SEK-62.70m
  • Incorporated2008
  • Employees26.00
  • Location
    Episurf Medical ABKarlavagen 60STOCKHOLM 114 49SwedenSWE
  • Phone+46 86120020
  • Websitehttps://episurf.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EPIS B:STO since
announced
Transaction
value
KlaraBo Empire Holding ABAnnounced26 Jan 202626 Jan 2026Announced39.67%40.41m
Frusipe Intressenter Target 1 ABAnnounced30 Dec 202530 Dec 2025Announced39.67%125.00m
Data delayed at least 15 minutes, as of Feb 10 2026 17:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qlife Holding AB290.00k-6.28m32.77m5.00------113.00-0.4088-3.030.0351-0.3360.0235.0930.53290,000.00-49.72-61.64-103.82-89.60-4,222.41-36.54-2,166.55-444.400.5089--2.61---79.51--76.60------
Miris Holding AB (publ)19.52m-3.93m39.06m9.00--1.81--2.00-8.82-8.8234.3416.180.70331.004.791,952,100.00-14.15-49.33-20.65-97.4785.0390.68-20.12-74.982.20-3.020.00--13.568.3553.96--8.55--
Luxbright AB11.49m-19.25m55.31m12.00--2.06--4.82-0.1644-0.16440.09680.20670.27887.732.68---46.74-56.30-59.61-66.28-6.22-79.12-167.60-450.361.22-83.810.1076--26.5279.40-9.86------
ScandiDos AB59.37m-1.38m57.01m25.00--1.3292.400.9602-0.0242-0.02421.040.75760.84161.525.602,283,539.00-1.96-8.71-3.04-14.6848.3052.29-2.33-10.670.7927--0.00--2.341.55102.23---11.62--
Neola Medical AB0.00-10.99m59.09m8.00--0.7531-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
SpectraCure AB (publ)1.42m-53.17m59.60m13.00--0.4287--41.92-0.165-0.1650.00520.24680.012--1.90109,384.60-44.68-13.14-49.10-14.07835.02243.69-3,739.03-592.49---197.290.0325---46.15-13.97-12.54--0.1962--
Kontigo Care AB29.13m-2.07m63.10m10.00--1.2517.442.17-0.0589-0.05890.82621.430.4487--7.97---3.190.296-3.980.4064125.51129.99-7.120.4638----0.00---3.667.41-367.61--17.15--
Episurf Medical AB15.60m-62.70m65.38m26.00--0.611--4.19-0.064-0.0640.01570.06450.1641--3.95577,777.80-65.44-45.67-74.89-50.07-----398.72-857.082.50--0.0844--23.5819.3919.83--6.68--
Redsense Medical AB (publ)30.67m302.00k67.59m4.00205.191.88114.362.200.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Scandinavian ChemoTech AB11.68m-8.70m74.62m1.00--12.97--6.39-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
Observe Medical ASA15.61m-115.05m84.34m4.00--3.48--5.40-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Iconovo AB1.59m-41.23m85.27m19.00--0.4628--53.74-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Data as of Feb 10 2026. Currency figures normalised to Episurf Medical AB's reporting currency: Swedish Krona SEK

Institutional shareholders

4.54%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Jun 202546.84m2.82%
Handelsbanken Fonder ABas of 31 Dec 202513.14m0.79%
Strand Kapitalf�rvaltning ABas of 31 Dec 20247.99m0.48%
Skandia Investment Management ABas of 28 Nov 20253.31m0.20%
SEB Funds ABas of 31 Dec 20252.73m0.16%
Storebrand Asset Management ASas of 30 Nov 20251.22m0.07%
Skandia Fonder ABas of 28 Nov 2025118.69k0.01%
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.